Identify cognitive decline in Parkinsons
- Trial ID
- NCT03402919
- Official Title
- The Comprehensive Assessment of Neurodegeneration and Dementia Study
- Goal
- Identify cognitive decline in Parkinsons
- Status
- RECRUITING
- Sponsor
- McGill University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1573 participants
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD), Lewy Body Disease(LBD), Mixed Dementia, Frontotemporal Dementia (FTD), Alzheimer Disease (AD), Cognitively Unimpaired, Subjective Cognitive Decline (SCD)
Plain-Language Summary
The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
Locations
- University of Calgary, Calgary, Alberta, Canada
- University of Alberta Hospital, Edmonton, Alberta, Canada
- Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada
- Island Health, Victoria, British Columbia, Canada
- Veteran's Memorial Building, Halifax, Nova Scotia, Canada
- Hamilton General Hospital, Hamilton, Ontario, Canada
- St. Joseph's Health Care London, London, Ontario, Canada
- Gait and Brain Lab, London, Ontario, Canada
- Bruyère Research Institute, Ottawa, Ontario, Canada
- Kawartha Centre, Peterborough, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- University Health Network Memory Clinic, Toronto, Ontario, Canada
- Baycrest Clinical Unit, Toronto, Ontario, Canada
- University of Waterloo, Waterloo, Ontario, Canada
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Jewish General Hospital/McGill Memory Clinic, Montreal, Quebec, Canada
- Clinique de cognition Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Hôpital Enfant-Jésus, Québec, Quebec, Canada
- Centre de recherche sur le vieillissement CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
- Who can participate?
- Participants must be between 50 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 19 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 5 months.